Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | OXER1 | Q8TDS5 | 7/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | IAPP | P10997 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004067 | 1.00 | TRPA1 (0.55) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL2998071 | 1.00 | TRPA1 (0.55) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL30924783 | 0.94 | TRPA1 (0.63) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL27856220 | 0.92 | TRPA1 (0.61) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL30924788 | 0.92 | TRPA1 (0.61) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL8444906 | 0.92 | TRPA1 (0.59) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL8444903 | 0.92 | TRPA1 (0.59) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL18142129 | 0.88 | TRPA1 (0.44) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL13180040 | 0.88 | TRPA1 (0.44) | TRPA1KDM4EOXER1ALOX12ALOX5 | |
| SCHEMBL3397099 | 0.88 | TRPA1 (0.44) | TRPA1KDM4EOXER1ALOX12ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2178399-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009009916-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | OR10J3, ALOX5, OR51E2 | TRPA1 6/4885KDM4E 4306/4885OXER1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.